IMTX

#2301
Immatics N.V. - Ordinary Shares
9.5 1 USD
+0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
9.45
9.54
Intervallo Annuale
8.17
12.40
Variazione giornaliera
+0.85%
Variazione Mensile
+10.32%
Variazione di 6 mesi
-1.76%
Variazione Annuale
-8.12%
Chiusura Precedente
9.4 3
Open
9.4 6
Minimo
9.4 5
Massimo
9.5 4
Volume
394
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Immatics N.V. current report, Q3 FY2026
6-K
Current report, Q2 FY2026
Immatics N.V. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Immatics N.V. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Immatics N.V. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Immatics N.V. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Immatics N.V. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Immatics N.V. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Immatics N.V. current report, Q2 FY2026
6-K
Current report, Q1 FY2026
Immatics N.V. current report, Q1 FY2026
6-K

2025

Annual report, Q4 FY2025
Immatics N.V. annual report, Q4 FY2025
20-F

Immatics N.V. current report, Q2 FY2025

Full document

Business Context and Reporting Period

This Form 6-K filing by Immatics N.V. reports on the Annual General Meeting of Shareholders (AGM) held on June 18, 2025. The filing primarily documents corporate governance actions and shareholder approvals rather than providing a detailed financial performance report for a specific quarter.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document confirms that shareholders approved the statutory annual accounts for the financial year ended December 31, 2024, but the numerical details of these accounts are not included in this report.

Material Changes and Corporate Actions

  • Board Composition: Shareholders approved the reappointment of Mr. P.A. Chambré and Ms. H.L. Mason as non-executive directors (Class II) and the appointment of Dr. A.S. Reicin as a new non-executive director (Class II).
  • Share Repurchase: The Board's authorization to acquire ordinary shares or depositary receipts was extended.
  • Compensation: The Company's 2025 stock option and incentive plan was approved.
  • Auditor: PricewaterhouseCoopers Accountants N.V. was instructed as the auditor for the financial year ending December 31, 2025.
  • Liability Discharge: The Board of directors received a discharge from liability regarding their duties for the year ended December 31, 2024.

Guidance, Outlook, and Risks

The filing does not contain management commentary on future financial guidance, operational outlook, specific risks, contingencies, or unusual items. The document is limited to the procedural outcomes of the AGM.

Investor Verification Checklist

  • Verify the full text of the statutory annual accounts for the year ended December 31, 2024, which were approved but not detailed in this filing.
  • Review the specific terms of the extended share repurchase authorization.
  • Examine the details of the newly approved 2025 stock option and incentive plan.
  • Confirm the background and qualifications of the newly appointed director, Dr. A.S. Reicin.

Notizie